A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
Tae Hwan KimShin-Seok LeeWon ParkYeong-Wook SongChang-Hee SuhSooKyoung KimYoung Nam LeeDae Hyun YooPublished in: Clinical drug investigation (2020)
Up to 5 years of CT-P13 treatment was safe and effective in patients with RA and AS, based on drug survival, incidence of TEAEs, and disease activity. Drug survival and safety were similar in naïve patients and switched groups, supporting switching from reference infliximab to CT-P13.
Keyphrases
- ankylosing spondylitis
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- image quality
- rheumatoid arthritis patients
- computed tomography
- dual energy
- contrast enhanced
- end stage renal disease
- randomized controlled trial
- newly diagnosed
- free survival
- magnetic resonance imaging
- adverse drug
- ejection fraction
- juvenile idiopathic arthritis
- positron emission tomography
- systematic review
- prognostic factors
- ulcerative colitis
- peritoneal dialysis
- risk factors
- emergency department
- patient reported outcomes
- combination therapy